CLL
Conference Coverage
Optimizing therapy in relapsed CLL: ibrutinib and beyond
CHICAGO – The efficacy of ibrutinib is durable for patients with relapsed chronic lymphocytic leukemia (CLL), and combination strategies are...
Conference Coverage
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Conference Coverage
Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL
CHICAGO – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic...
Conference Coverage
Sequential triple therapy produces high response rates in CLL
“Sequential triple-T” (tailored and targeted treatment) aimed at complete eradication of MRD looks promising for CLL.
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
Conference Coverage
NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”...
Conference Coverage
iFCG achieves high MRD-negative remission in untreated CLL
NEW YORK – Could a three-course regimen for CLL have a positive affect on treatment?
Conference Coverage
ECG finding predicts AFib in ibrutinib-treated CLL
NEW YORK – Left atrial abnormality as measured by electrocardiogram in ibrutinib-treated patients with chronic lymphocytic leukemia can identify...
Conference Coverage
In good-candidate CLL, don’t wait too long for alloHCT
NEW YORK – Allogeneic hematopoietic stem cell transplantation (alloHCT) using HLA-compatible donors results in excellent long-term progression-...
Conference Coverage
Ibrutinib response in CLL/SLL less affected by select risk factors
NEW YORK – Risk factors associated with poor outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia patients treated with standard...